/
We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient s own anatomy. Our growing product portfolio is purposefully designed to leverage the patient s natural healing response while minimizing long-term exposure to permanent synthetic…
The business is unprofitable at the operating level (-42.05% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 15.8% YoY with margins expanding 7.2pp.
Negative free cash flow of -$29M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$81M
▲ +15.8% YoY
Net Income (TTM)
-$40M
▼ -2.6% YoY
Op. Margin
-41.84%
▲ +7.2pp YoY
ROIC
-49.69%
▲ +1.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$30M
▲ +32.7% YoY
Op. Cash Flow (TTM)
-$30M
▲ +32.2% YoY
Net Debt
$17M
Cash & Equiv.
$40M
5Y CAGR: +34.5%
Continue Research